Buruli ulcer medical therapy

This page is about clinical aspects of the disease.  For microbiologic aspects of the causative organism(s), see Mycobacterium ulcerans.

Buruli ulcer Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Buruli ulcer from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Buruli ulcer medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Buruli ulcer medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Buruli ulcer medical therapy
CDC on Buruli ulcer medical therapy
Buruli ulcer medical therapy in the news
Blogs on Buruli ulcer medical therapy
Directions to Hospitals Treating Buruli ulcer
Risk calculators and risk factors for Buruli ulcer medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Antibiotics currently play little part in the treatment of Buruli ulcer. Recommended drugs include rifampin, streptomycin and dapsone.

Medical Therapy

Acute Pharmacotherapy

The WHO currently recommend rifampicin and streptomycin for eight weeks in the hope of reducing the need for surgery. The combination of rifampicin and clarithromycin has been used for many years in Australia. Rifampicin must never be used alone because the bacterium quickly becomes resistant.

There are a number of experimental treatments currently being investigated:

• Sitafloxacin and rifampicin is a synergistic combination that only been trialled in mice.
• Rifalazil is a rifamycin antibiotic that appears to be more potent than rifampicin that has only been trialled in mice.
• Epiroprim and dapsone are synergistic when used in combination (in vitro studies only at present)
• Diarylquinoline shows high potency in vitro

In a small series of eight patients, local heat at 40°C led to complete healing without surgery (except the initial removal of dead tissue).

Antimicrobial Regimen

• Mycobacterium ulcerans

• 1. Preulcerative lesions

• Excision and primary closure, Rifampin monotherapy, or heat therapy

• 2. Established ulcers

• Most antimycobacterial agents are ineffective for the treatment of the ulcer; Surgical debridement combined with skin grafting is the usual treatment of choice

• 3. Control complications of the ulcer

• Preferred regimen: Clarithromycin AND Rifampin

References

Template:WS